Sangair

Target group

PhD students

About the company

Sangair is a company developing a disruptive medical device to support treatment of Sepsis as well as other potential symptoms. The developed device is treating blood extracorporeal with oxygen-gas mixed with small amounts of ozone gas.

The data to point have been published in 2 different articles and show a promising immunomodulating effects as well as lowering the number of viable bacteria present in blood.

The company is currently conducting pre-clinical trials, with the focus of lowering inflammation when having sepsis.

The project

Ozone has been considered a potential beneficial treatment strategy for different pathologies for quite some time. However, there is a lack of systematic and strategic approaches to determine the actual benefits of this treatment in clinically relevant models. This project aims to provide a strategic analysis of ozone and its effect in different scenarios of pathology. An extensive literature search will generate data for a systematic review and meta-analysis on the topic. Expected results are mainly a clarified and strategic output of ozone efficacy in different disease models and systems. The results will likely be published in an open-access, peer-review, high-impact journal where a co-authorship will be offered.

Suggested areas of focus:
Lowering inflammation by broad effects on cytokines,
Lowering the number of anti-oxidants in blood à lowering risks of metastatic cancer

Innomedicum, Karolinska Institute

Time period: 1-month, full time. Preferred start November 1st or January 1st.

The candidate

The students should have significant knowledge and skills in literature search systems (Scopus and PubMed). A strong research interest in mandatory. Skillsets like problem-solving and independence are expected, and records of recent published meta-analysis are meriting.

Contact information

Name: Henrik Rundgren

Email: Henrik.rundgren@sangair.se       

Telephone: 0707-190971
Company website: www.sangair.se